Small Swedish Biotech Cyxone’s US CEO Has ‘Big Plans’
Listing On Nasdaq Stockholm, Growing Pipeline And Finding Partners
Executive Summary
Swedish biotech Cyxone’s CEO tells Scrip about its aims to become a cutting-edge developer of disease-modifying treatments for rheumatoid arthritis and multiple sclerosis, but says the Scandinavian industry needs a ‘mindset change’.